Check-Cap Ltd. (CHEK)
| Market Cap | 68.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.84M |
| Shares Out | 7.99M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $1.41 |
| Previous Close | $1.53 |
| Change ($) | -0.12 |
| Change (%) | -7.84% |
| Day's Open | 1.49 |
| Day's Range | 1.37 - 1.56 |
| Day's Volume | 2,967,285 |
| 52-Week Range | 0.24 - 2.93 |
The technology appears safe, but performance versus standard of care requires a larger, expensive study. It will take a couple years to get readouts from the pivotal US study, providing a lack...
Check-Cap Ltd. (CHEK) stock is on the rise Monday despite a lack of news from the maker of the C-Scan colorectal cancer screening device.
CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ISFIYA, Israel, July 23, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the developme...
CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ISFIYA, Israel, June 5, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan®, th...
ISFIYA, Israel, May 27, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the developmen...
CheckCap Ltd. (CHEK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Check-Cap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Check-Cap announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.
About CHEK
Check-Cap, a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, whic... [Read more...]
| Industry Diagnostics & Research | IPO Date Feb 19, 2015 |
| CEO Guy Neev | Employees 64 |
| Stock Exchange NASDAQ | Ticker Symbol CHEK |
Analyst Forecasts
According to one analyst, the rating for Check-Cap stock is "Buy" and the 12-month stock price forecast is 1.75.